Advertisement

Drugs

, Volume 68, Issue 18, pp 2561–2573 | Cite as

Current and Emerging Management Options for Hereditary Angioedema in the US

  • Tolly G. Epstein
  • Jonathan A. Bernstein
Leading Article

Abstract

Hereditary angioedema (HAE) is a rare disorder characterized by recurrent attacks of swelling that may involve multiple anatomical locations. In the majority of patients, it is caused by a functional or quantitative defect in the C1 inhibitor (C1-INH), which is an important regulator of the complement, fibrinolytic, kallikrein-kinin and coagulation systems. Standard treatments used for other types of angioedema are ineffective for HAE. Traditional therapies for HAE, including fresh frozen plasma, ε-aminocaproic acid and danazol, may be well tolerated and effective in some patients; however, there are limitations both in their safety and efficacy.

Several novel therapies have completed phase III trials in the US, including: (i) plasma-derived C1-INH replacement therapies (Berinert P® and Cinryze®); (ii) a recombinant C1-INH replacement therapy (conestat alfa; Rhucin®); (iii) a kallikrein inhibitor (ecallantide [DX-88]); and (iv) a bradykinin-2-receptor antagonist (icatibant). Both Berinert P® and Cinryze® are reported to have excellent efficacy and safety data from phase III trials. Currently, only Cinryze® has been approved for prophylactic use in the US. US FDA approval for other novel agents to treat HAE and for the use of Cinryze® in the treatment of acute attacks is pending.

Keywords

Fresh Freeze Plasma Danazol Hereditary Angioedema Icatibant Ecallantide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

We would like to thank Richard Bruns, RN, CRC, Christopher Codispoti, MD, Haejin Kim, MD, and Maziar Rezvani, MD, for taking active roles in conducting hereditary angioedema clinical trials at the University of Cincinnati. Tolly Epstein, MD, has served as a sub-investigator on clinical research studies for Pharming and Dyax. Jonathan Bernstein, MD, has served as a principal investigator for studies conducted by Lev, Pharming, CSL-Behring, Dyax and Jerini. No sources of funding were used to assist in the preparation of this review.

References

  1. 1.
    Bowen T, Cicardi M, Bork K, et al. Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol 2008; 100 (1 Suppl. 2): S30–40PubMedCrossRefGoogle Scholar
  2. 2.
    Bernstein IL. Hereditary angioedema: a current state-of-the-art review, II: historical perspective of non-histamine-induced angioedema. Ann Allergy Asthma Immunol 2008; 100 (1 Suppl. 2): S2–6PubMedCrossRefGoogle Scholar
  3. 3.
    Cicardi M, Bergamaschini L, Cugno M, et al. Pathogenetic and clinical aspects of C1 inhibitor deficiency. Immunobiology 1998; 199(2): 366–76PubMedCrossRefGoogle Scholar
  4. 4.
    Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71(4): 206–15Google Scholar
  5. 5.
    Roche O, Blanch A, Caballero T, et al. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005; 94(4): 498–503PubMedCrossRefGoogle Scholar
  6. 6.
    Bork K, Gül D, Hardt J, et al. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med 2007; 120(11): 987–92PubMedCrossRefGoogle Scholar
  7. 7.
    Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal Cl inhibitor. Biochem Biophys Res Commun 2006; 343(4): 1286–9PubMedCrossRefGoogle Scholar
  8. 8.
    Frank MM. Hereditary angioedema: the clinical syndrome and its management in the United States. Immunol Allergy Clin North Am 2006; 26(4): 653–68PubMedCrossRefGoogle Scholar
  9. 9.
    Zuraw BL. Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema. Out with the old and in with the new? Ann Allergy Asthma Immunol 2008; 100 (1 Suppl. 2): S13–8sPubMedCrossRefGoogle Scholar
  10. 10.
    Davis 3rd AE. Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol 2008; 100 (1 Suppl. 2): S7–12PubMedCrossRefGoogle Scholar
  11. 11.
    Bernstein JA. Hereditary angioedema: a current state-of-the-art review, VIII: current status of emerging therapies. Ann Allergy Asthma Immunol 2008; 100 (1 Suppl. 2): S41–6PubMedCrossRefGoogle Scholar
  12. 12.
    Nielsen EW, Gran JT, Straume B, et al. Hereditary angio-oedema: new clinical observations and autoimmune screening, complement and kallikrein-kinin analyses. J Intern Med 1996; 239(2): 119–30PubMedCrossRefGoogle Scholar
  13. 13.
    Cedzynski M, Madaliñski K, Gregorek H, et al. Possible disease-modifying factors: the mannan-binding lectin pathway and infections in hereditary angioedema of children and adults. Arch Immunol Ther Exp (Warsz) 2008; 56(1): 69–75CrossRefGoogle Scholar
  14. 14.
    Agostoni A, Cicardi M, Cugno M, et al. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology 1999; 44(1-2): 21–5PubMedCrossRefGoogle Scholar
  15. 15.
    Goring HD, Bork K, Späth PJ, et al. Hereditary angioedema in the German-speaking region [in German]. Hautarzt 1998; 49(2): 114–22PubMedCrossRefGoogle Scholar
  16. 16.
    Banerji A, Sloane DE, Sheffer AL. Hereditary angioedema: a current state-of-the-art review, V: attenuated androgens for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2008; 100 (1 Suppl. 2): S19–22PubMedCrossRefGoogle Scholar
  17. 17.
    Agostoni A, Cicardi M, Martignoni GC, et al. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. J Allergy Clin Immunol 1980; 65(1): 75–9PubMedCrossRefGoogle Scholar
  18. 18.
    Gelfand JA, Sherins RJ, Ailing DW, et al. Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. N Engl J Med 1976; 295(26): 1444–8PubMedCrossRefGoogle Scholar
  19. 19.
    Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol 1981; 68(3): 181–7PubMedCrossRefGoogle Scholar
  20. 20.
    Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008; 100(2): 153–61PubMedCrossRefGoogle Scholar
  21. 21.
    Herrmann G, Schneider L, Krieg T, et al. Efficacy of danazol treatment in a patient with the new variant of hereditary angio-oedema (HAE III). Br J Dermatol 2004; 150(1): 157–8PubMedCrossRefGoogle Scholar
  22. 22.
    Hosea SW, Santaella ML, Brown EJ, et al. Long-term therapy of hereditary angioedema with danazol. Ann Intern Med 1980; 93(6): 809–12PubMedGoogle Scholar
  23. 23.
    Cicardi M, Bergamaschini L, Cugno M, et al. Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J Allergy Clin Immunol 1991; 87(4): 768–73PubMedCrossRefGoogle Scholar
  24. 24.
    Cicardi M, Castelli R, Zingale LC, et al. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997; 99(2): 194–6PubMedCrossRefGoogle Scholar
  25. 25.
    Brunskill PJ. The effects of fetal exposure to danazol. Br J Obstet Gynaecol 1992; 99(3): 212–5PubMedCrossRefGoogle Scholar
  26. 26.
    Farkas H, Varga L, Széplaki G, et al. Management of hereditary angioedema in pediatric patients. Pediatrics 2007; 120(3): e713–22PubMedCrossRefGoogle Scholar
  27. 27.
    Sheffer AL, Fearon DT, Austen KF. Hereditary angioedema: a decade of management with stanozolol. J Allergy Clin Immunol 1987; 80(6): 855–60PubMedCrossRefGoogle Scholar
  28. 28.
    Zuraw BL. Current and future therapy for hereditary angioedema. Clin Immunol 2005; 114(1): 10–6PubMedCrossRefGoogle Scholar
  29. 29.
    Church JA. Oxandrolone treatment of childhood hereditary angioedema. Ann Allergy Asthma Immunol 2004; 92(3): 377–8PubMedCrossRefGoogle Scholar
  30. 30.
    Frank MM, Sergent JS, Kane MA, et al. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema: a double-blind study. N Engl J Med 1972; 286(15): 808–12PubMedCrossRefGoogle Scholar
  31. 31.
    Blohme G. Treatment of hereditary angioneurotic oedema with tranexamic acid: a random double-blind cross-over study. Acta Med Scand 1972; 192(4): 293–8PubMedGoogle Scholar
  32. 32.
    Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29(3): 236–61PubMedCrossRefGoogle Scholar
  33. 33.
    Cooper Jr JR, Abrams J, Frazier OH, et al. Fatal pulmonary microthrombi during surgical therapy for end-stage heart failure: possible association with antifibrinolytic therapy. J Thorac Cardiovasc Surg 2006; 131(5): 963–8PubMedCrossRefGoogle Scholar
  34. 34.
    Seymour BD, Rubinger M. Rhabdomyolysis induced by epsilon-aminocaproic acid. Ann Pharmacother 1997; 31(1): 56–8PubMedGoogle Scholar
  35. 35.
    Jaffe CJ, Atkinson JP, Gelfand JA, et al. Hereditary angioedema: the use of fresh frozen plasma for prophylaxis in patients undergoing oral surgery. J Allergy Clin Immunol 1975; 55(6): 386–93PubMedCrossRefGoogle Scholar
  36. 36.
    Atkinson JC, Frank MM. Oral manifestations and dental management of patients with hereditary angioedema. J Oral Pathol Med 1991; 20(3): 139–42PubMedCrossRefGoogle Scholar
  37. 37.
    Farkas H, Gyeney L, Gidófalvy E, et al. The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures. J Oral Maxillofac Surg 1999; 57(4): 404–8PubMedCrossRefGoogle Scholar
  38. 38.
    Longhurst HJ. Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? Int J Clin Pract 2005; 59(5): 594–9PubMedCrossRefGoogle Scholar
  39. 39.
    Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2007; 98(4): 383–8PubMedCrossRefGoogle Scholar
  40. 40.
    Bork K, Meng G, Staubach P, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119(3): 267–74PubMedCrossRefGoogle Scholar
  41. 41.
    Cicardi M, Zingale L. How do we treat patients with hereditary angioedema. Transfus Apher Sci 2003; 29(3): 221–7PubMedCrossRefGoogle Scholar
  42. 42.
    Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001; 161(5): 714–8PubMedCrossRefGoogle Scholar
  43. 43.
    Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996; 334(25): 1630–4PubMedCrossRefGoogle Scholar
  44. 44.
    Bork K, Ressel N. Sudden upper airway obstruction in patients with hereditary angioedema. Transfus Apher Sci 2003; 29(3): 235–8PubMedCrossRefGoogle Scholar
  45. 45.
    Bork K, Hardt J, Schicketanz KH, et al. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 2003; 163(10): 1229–35PubMedCrossRefGoogle Scholar
  46. 46.
    Bork K, Meng G, Staubach P, et al. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 2005; 45(11): 1774–84PubMedCrossRefGoogle Scholar
  47. 47.
    Bork K, Witzke G. Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol 1989; 83(3): 677–82PubMedCrossRefGoogle Scholar
  48. 48.
    De Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus Apher Sci 2003; 29(3): 247–54PubMedCrossRefGoogle Scholar
  49. 49.
    Frank MM. Hereditary angiodema: a current state-of-the-art review, VI: novel therapies for hereditary angioedema. Ann Allergy Asthma Immunol 2008; 100 (1 Suppl. 2): S23–9PubMedCrossRefGoogle Scholar
  50. 50.
    Martinez-Saguer I, Muller W, Pursun EA, et al. Pharmacokinetic parameters of Cl inhibitor concentrate in 40 patients with hereditary angioedema (HAE): a prospective study [abstract]. Haemophilia 2002; 8: 574Google Scholar
  51. 51.
    Bork K, Staubach P, Hardt J. Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema. Allergy 2008; 63(6): 751–7PubMedCrossRefGoogle Scholar
  52. 52.
    Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 114 (3 Suppl.): S51–131PubMedCrossRefGoogle Scholar
  53. 53.
    Bernstein JA, Levy R, Wasserman RL, et al. Treatment of acute abdominal and facial attacks of hereditary angioedema (HAE) with human C1 esterase inhibitor (C1-INH): results of a global, multicenter, randomized, placebo-controlled, phase ii/iii study (I.M.P.A.C.T. 1) [abstract]. J Allergy Clin Immunol 2008; 121(3): 795CrossRefGoogle Scholar
  54. 54.
    Tateishi J, Kitamoto T, Mohri S, et al. Scrapie removal using Planova virus removal filters. Biologicals 2001; 29(1): 17–25PubMedCrossRefGoogle Scholar
  55. 55.
    Terpstra FG, Kleijn M, Koenderman AH, et al. Viral safety of C1-inhibitor NF. Biologicals 2007; 35(3): 173–81PubMedCrossRefGoogle Scholar
  56. 56.
    Siegal F, Chairman, Blood Products Advisory Committee Meeting. United States of America Department of Health and Human Services Food and Drug Administration Center for Biologies Evaluation and Research Blood Products Advisory Committee. Meeting Open Session [commercial transcribing service, unedited]; 2008 May 2; Rockville (MD)Google Scholar
  57. 57.
    Codispoti CD, Rezvani M, Bernstein JA. Successful use of C1 inhibitor during mitral valve replacement surgery on cardio-pulmonary bypass. Ann Allergy 2008; 101(2): 220CrossRefGoogle Scholar
  58. 58.
    Lev Pharmaceuticals. Lev announces FDA Advisory Committee unanimously recommends approval of Cinryze® for hereditary angioedema [online]. Available from URL: http://www.medicalnewstoday.com/articles/lO6662.php [Accessed 2008 Jun 25]
  59. 59.
    van Doorn MB, Burggraaf J, van Dam T, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005; 116(4): 876–83PubMedCrossRefGoogle Scholar
  60. 60.
    Choi G, Soeters MR, Farkas H, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 2007; 47(6): 1028–32PubMedCrossRefGoogle Scholar
  61. 61.
    Nuijens J, Verdonk R, Gianneti C, et al. Clinical studies of recombinant human Cl inhibitor (rhC1-INH) in patients with acute attacks of hereditary angioedema [abstract]. J Allergy Clin Immunol 2008; 121(3): 797CrossRefGoogle Scholar
  62. 62.
    Cicardi M, Perricone R, Cancian M, et al. A randomised, placebo-controlled, double-blind, phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema [abstract]. XXII International Complement Workshop; 2008 Sep 28–Oct 2; BaselGoogle Scholar
  63. 63.
    Pharming. Pharming announces positive results with north American randomized trial with Rhucin® [online]. Available from URL: http://www.pharming.com/index.php7act-=show&pg=418 [Accessed 2008 Jun 25]
  64. 64.
    Williams A, Baird LG. DX-88 and HAE: a developmental perspective. Transfus Apher Sci 2003; 29(3): 255–8PubMedCrossRefGoogle Scholar
  65. 65.
    Levy JH, O’Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Investig Drugs 2006; 15(9): 1077–90PubMedCrossRefGoogle Scholar
  66. 66.
    Cicardi M, Zingale L, Zanichelli A, et al. Established and new treatments for hereditary angioedema: an update. Mol Immunol 2007; 44(16): 3858–61PubMedCrossRefGoogle Scholar
  67. 67.
    Schneider L, Lumry W, Vegh A, et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 2007; 120(2): 416–22PubMedCrossRefGoogle Scholar
  68. 68.
    Caballero T, Lopez-Serrano C. Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J Allergy Clin Immunol 2006; 117(2): 476–7; discussion 477PubMedCrossRefGoogle Scholar
  69. 69.
    Beck TR, Baird L. Anaphylactic reaction and antibodies to DX-88 (kallikrien inhibitor) in a patient with hereditary angioedema [letter]. J Allergy Clin Immunol 2006; 117: 477CrossRefGoogle Scholar
  70. 70.
    Bas M, Adams V, Suvorava T, et al. Nonallergic angioedema: role of bradykinin. Allergy 2007; 62(8): 842–56PubMedCrossRefGoogle Scholar
  71. 71.
    Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (icatibant). J Allergy Clin Immunol 2007; 119(6): 1497–503PubMedCrossRefGoogle Scholar
  72. 72.
    Icatibant: HOE 140, JE 049, JE 049. Drugs R D 2005; 6 (4): 239–44Google Scholar
  73. 73.
    Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002; 109(8): 1057–63PubMedGoogle Scholar
  74. 74.
    Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist. Br J Clin Pharmacol 1994; 38(4): 317–21PubMedCrossRefGoogle Scholar
  75. 75.
    Walters L. Jerini receives positive CHMP opinion recommending European approval for Icatibant in the treatment of HAE [online]. Available from URL: http://www.hospitalpharma.com/PressReleases/pressrel.asp?ROW_ID=3698 [Accessed 2008 Jun 25]
  76. 76.
    Wouters D, Wagenaar-Bos I, van Ham M. C1-inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1-inhibitor. Expert Opin Biol Ther 2008 Aug; 8(8): 1225–40PubMedCrossRefGoogle Scholar
  77. 77.
    Nuijens JH, Eerenberg-Belmer AJ, Huijbregts CC, et al. Proteolytic inactivation of plasma C1-inhibitor in sepsis. J Clin Invest 1989; 84(2): 443–50PubMedCrossRefGoogle Scholar
  78. 78.
    Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 1995; 91(2): 393–402PubMedCrossRefGoogle Scholar
  79. 79.
    Horstick G, Heimann A, Götze O, et al. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation 1997; 95(3): 701–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Department of Internal Medicine, Division of Immunology/AllergyUniversity of Cincinnati Medical Center, Academic Health CenterCincinnatiUSA

Personalised recommendations